查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
被忽视的热带病治疗的全球市场2022-2029
市场调查报告书
商品编码
1153807

被忽视的热带病治疗的全球市场2022-2029

Global Neglected Tropical Disease Treatment Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

在预测期内（2022-2029 年），被忽视热带病治疗的全球市场规模预计将以 5.55% 的复合年增长率增长。

被忽视的热带病 (NTD) 是 20 种主要在热带地区发现的疾病，对穷人、妇女和儿童的影响尤为严重。这些疾病对人们的健康、社会和经济造成破坏性影响。许多被忽视的热带病 (NTD) 可以用现有药物治疗。有些治疗很容易应用，不需要专家的帮助。同时，药物治疗可用于某些被忽视的热带病，但并不总能到达最需要的人手中。

市场动态

被忽视的热带病治疗市场的增长背后有几个因素，包括全球组织的努力、发达国家移民人口的增加以及发展中国家缺乏足够的卫生设施和意识。

针对被忽视的热带病的药物发现不断增加的资金预计将推动市场增长。

最近为平衡对被忽视的热带病和其他疾病的投资所做的国际努力开始改变这一局面。例如，根据第一份年度报告，估计每年的资金缺口为 3 亿美元。根据第三次进展报告，製药公司已承诺到2020年为10种疾病提供价值178亿美元的药物。此外，世卫组织最近欢迎设立一个 1 亿美元的基金，以帮助消除两种毁灭性的传染性 NTD:盘尾丝虫病（河盲症）和淋巴丝虫病（像皮病）。阿布扎比王储和比尔及梅琳达盖茨基金会各捐助 2000 万美元，其余 6000 万美元来自与其他捐助者和基金会的合作。由于这些原因，预计市场将成为预测期内的推动力。

约束

由于对被忽视的热带病的治疗认识不足，销售额正在下降。被忽视的热带病无法获□□得尖端药物，医疗保健系统也不完善。因此，预计上述因素将在预测期内成为障碍。

行业分析

被忽视的热带病治疗市场根据波特五力、供应链、定价分析和监管批准等各种行业因素对市场进行了深入分析。

内容

第一章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第四章市场动态

  • 市场影响因素
    • 司机
      • 由于针对被忽视的热带病的药物发现资金增加，预计市场会增长。
    • 约束因素
      • 认知度低预计会阻碍预测期内的市场增长。
    • 市场机会
    • 影响分析

第五章行业分析

  • 搬运工的五种力量
  • 未满足的需求
  • 供应链
  • 定价分析
  • 监管分析

第 6 章 COVID-19 分析

  • COVID-19 市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按疾病类型分类

  • 布鲁里溃疡
  • 南美锥虫病
  • 登革热/基孔肯雅热
  • 德古拉病
  • 包虫病
  • 食物中毒吸虫
  • 非洲人类锥虫病
  • 利甚曼病
  • 麻风病
  • 淋巴丝虫病
  • 菌丝体、黑色素瘤芽生菌病
  • 盘尾丝虫病
  • 狂犬病
  • 疥疮
  • 血吸虫病
  • 土传蠕虫病
  • 蛇咬伤
  • 绦虫病/囊尾蚴病
  • 沙眼
  • 溜溜球

第 8 章按治疗类型分类

  • 药物治疗
  • 疫苗

第 9 章（按销售渠道）

  • 医院药房
  • 零售药房
  • 在线药店

第10章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第11章竞争格局

  • 竞争场景
  • 市场情况/份额分析
  • 併购分析

第12章公司简介

  • Bayer AG
    • 公司概况
    • 产品组合和说明
    • 主要亮点
    • 财务摘要
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Novartis AG
  • Pfizer Inc.
  • Cipla Limited
  • AbbVie Inc.
  • Takeda Pharmaceuticals
  • Serum Institute of India
  • Visterra Inc.

第13章 被忽视的热带病治疗的全球市场-DataM

简介目录
Product Code: DMPH1231

Market Overview

The global neglected tropical disease treatment market size was valued US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 5.55% during the forecast period (2022-2029).

Neglected tropical diseases (NTDs) are a series of 20 diseases mostly found in tropical areas, disproportionately impacting poor people, women and children. People suffer from terrible health, societal, and economic effects due to these disorders. Many neglected tropical diseases (NTDs) are curable with existing medications. Certain therapies are simple to apply and do not necessitate the use of medical specialists. In contrast, while medication therapies are available for several NTDs, they do not always reach the people who need them the most.

Market Dynamics

The neglected tropical disease treatment market growth is driven by several factors, such as initiatives taken by several organizations globally, increase in migrant population in developed nations, and a lack of proper sanitation and awareness in developing countries.

Increasing funding for drug discovery for the neglected tropical disease is expected to drive market growth.

Recent international efforts to balance the investment between neglected and other diseases have begun reshaping the landscape. For instance, according to the first annual report, the estimated financing gap is $300 million per year. According to the third progress report, pharmaceutical companies have pledged medications worth $17.8 billion for the ten diseases until 2020. Moreover, WHO recently welcomed the establishment of a $100 million fund to aid in eradicating two devastating infectious NTDs: onchocerciasis (river blindness) and lymphatic filariasis (elephantiasis). The Crown Prince of Abu Dhabi and the Bill and Melinda Gates Foundation have each pledged US$20 million, with the remaining US$60 million generated through collaboration with other donors and foundations. Thus, from the above statements, the market is expected to drive in the forecast period.

Restraint

Lack of awareness cause sales of neglected tropical disease treatment options to fall. These nations lack access to cutting-edge drugs and an inadequate healthcare system. Thus, the abovementioned factors are expected to get hampered in the forecast period.

Industry Analysis

The neglected tropical disease treatment market provides in-depth analysis of the market based on various industry factors such as porter five forces, supply chain, pricing analysis, regulatory approvals etc.

Segment Analysis

Medication segment is expected to hold the largest market share in neglected tropical disease treatment market.

The medication segment accounted for the largest market share in 2021. The segment is further sub-segmented into antibiotic, antiparasitic, anti-inflammatory, anti-microbial, and anti-fungal. Among medications, antiparasitic drugs are most commonly used for treating neglected tropical diseases, as many of them are caused by parasitic transmission. The high prevalence of parasite-infected diseases in remote and rural areas and urban slums due to poor sanitation practices have increased the demand for antiparasitic drugs. Several FDA-approved antiparasitic drugs are on the market to treat neglected tropical diseases, and many major players are developing new and advanced medicines for faster treatment. For instance, on November 8, 2021, Orlando, Fla-based Profounda announced the Food and Drug Administration (FDA) approved an Orphan Drug Designation for the use of the company's therapy, miltefosine (Impavido), to treat invasive candidiasis. Miltefosine is an oral, FDA-approved treatment for visceral, mucosal, and cutaneous leishmaniasis in individuals aged 12 and up. Thus, from the above statements, the markert segment accounted for the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global neglected tropical disease treatment market

North America accounted for the largest market share in 2021. Owing to the highly aware population, advanced healthcare infrastructure, favorable government initiatives, increase in migrant population over the region and presence of major companies. North America has the requisite insect vectors, the climate, and the ecology to support the presence of these diseases and, of course, a susceptible human population to become infected. North America has the requisite insect vectors, the climate, and the ecology to support the presence of these diseases and, of course, a susceptible human population to become infected. According to the Centers for Disease Control and Prevention (CDC), Chagas disease is the new HIV in the U.S., with around 300,000 people suffering from it and about 315 babies born with it yearly. Moreover, in March 2019, Novartis joined the Global Chagas Disease Coalition and announced the first multinational, prospective, randomized study in people with chronic Chagas cardiomyopathy. Thus, from the above statements, the North American region accounted for the largest market share in the forecast period.

Competitive Landscape

Major key players in the neglected tropical disease treatment market are: Bayer AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Novartis AG, Pfizer Inc., Cipla Limited, AbbVie Inc., Takeda Pharmaceuticals, Serum Institute of India and, Visterra Inc.

Bayer AG:

Overview:

Bayer is a Life Science company with a more than 150-year history and core health care and agriculture competencies. The Bayer Group is managed as a life science company with three divisions Pharmaceuticals, Consumer Health and Crop Science, which are also our reporting segments. The Enabling Functions support the operational business. In 2019, the Bayer Group comprised 392 consolidated companies in 87 countries. The Pharmaceuticals division focuses on prescription products, especially cardiology and women's healthcare, and specialty therapeutics in oncology, hematology and ophthalmology. The Consumer Health division markets mainly nonprescription (OTC) products in the dermatology, nutritional supplement, analgesic, digestive health, cold, allergy, sinus and flu categories.

Product Portfolio:

Praziquantel (Biltricide): This medication is used to treat infections of certain parasites (such as Schistosoma and liver flukes). Curing parasitic infections helps to improve your health and quality of life. Praziquantel belongs to a class of drugs known as anthelmintics. It works by killing the parasites.

The global neglected tropical disease treatment market report would provide an access to an approx. 45+ market data table, 40+ figures and 180 pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing funding for drug discovery for the neglected tropical disease is expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. Lack of awareness are expected to get hampered in the forecast period.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces
  • 5.2. Unmet Needs
  • 5.3. Supply Chain
  • 5.4. Pricing Analysis
  • 5.5. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Disease Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 7.1.2. Market Attractiveness Index, By Disease Type Segment
  • 7.2. Buruli Ulcer*
      • 7.2.1.1. Introduction
      • 7.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Chagas Disease
  • 7.4. Dengue and Chikungunya
  • 7.5. Dracunculiasis
  • 7.6. Echinococcosis
  • 7.7. Foodborne Trematodiases
  • 7.8. Human African Trypanosomiasis
  • 7.9. Leishmaniasis
  • 7.10. Leprosy
  • 7.11. Lymphatic Filariasis
  • 7.12. Mycetoma, Chromoblastomycosis
  • 7.13. Onchocerciasis
  • 7.14. Rabies
  • 7.15. Scabies
  • 7.16. Schistosomiasis
  • 7.17. Soil-transmitted Helminthiases
  • 7.18. Snakebite Envenoming
  • 7.19. Taeniasis/Cysticercosis
  • 7.20. Trachoma
  • 7.21. Yaws

8. By Treatment Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.1.2. Market Attractiveness Index, By Treatment Type Segment
  • 8.2. Medication*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Vaccines

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel Segment
  • 9.2. Hospital pharmacies*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Retail pharmacies
  • 9.4. Online pharmacies

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Bayer AG*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. F. Hoffmann-La Roche Ltd.
  • 12.3. GlaxoSmithKline Plc
  • 12.4. Novartis AG
  • 12.5. Pfizer Inc.
  • 12.6. Cipla Limited
  • 12.7. AbbVie Inc.
  • 12.8. Takeda Pharmaceuticals
  • 12.9. Serum Institute of India
  • 12.10. Visterra Inc.

LIST NOT EXHAUSTIVE

13. Global Neglected Tropical Disease Treatment Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Applications
  • 13.3. Contact Us